COMPANY PROFILE

EverZom

Explore full profile

A key asset to the future health of an ageing population

Paris, FranceFounded 2019Biotech & Life Sciences

Valuation $25–50M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About EverZom

Developer of a GMP-compliant extracellular vesicle manufacturing platform based on a unique proprietary technology designed for pharmaceutical researchers. The company's extracellular vesicles have protective and reparative properties representing an important therapeutic tool, thereby enabling healthcare professionals to use them to overcome the failure of an organ, restoring its function and homeostasis. Keywords: Pharmaceuticals and Biotechnology, Bio Medicine Company, Bio Medicine Platform, Bio Production Systems, Biomedical Research, Bioproduction Facility, Nanomedecine Biotech Company, Regenerative Medicine.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Paris, France
Employees: 24
Open positions: None listed
Dealroom signal: 84.2/100
Industry: Health
Sub-industry: BioTechnology, Health Platform
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Regenerative Medicine, Spinout, EIC, Biotech and Pharma, EIC Fund, EIT Health, biotech medtech and e-health
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Oct 2025	$11M	$44M	Paris Business Angels · Capital Cell · Sorbonne Venture · Capital Grand Est	↗
EARLY VC✓Equity / VC	Aug 2025	$0	—	EIC Fund	—

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

EverZom website traffic

Latest recorded traffic for EverZom is 920 monthly website visits, down 56.2% over the last three months. EverZom's team grew 26.3% over the past year.

Latest monthly visits920 3-month web change-56.2% 1-year team growth+26.3%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational	57	$26M	$70M
SISmart ImmuneDevelops off-the-shelf allogeneic T-cell progenitor therapies to restore a fully functional immune system in patients with cancer and severe infections	Paris, France	Operational
OMOMINIOmini develops biosensing devices for immediate blood tests at the patient bedside	Paris, France	Operational
THTHERAPANACEADevotion to Innovation, Compassion for Patients, Artificial Intelligence for Cancer Care	Paris, France	Operational
GRGraphealGrapheal develops and manufactures true monolayer graphene on flexible substrates, enabling next-generation sustainable and cost-effective sensor platforms especially when coupled with IOTs	Grenoble, France	Operational
MAMAbSilicoComputational solutions for antibody discovery using Artificial Intelligence and Machine Learning	Tours, France	Operational
SLScienta LabAI-powered Precision Immunology	Gif-sur-Yvette, France	Operational
HEHealshapePersonalized, resorbable bioprosthesis for natural breast reconstruction	Nantes, France	Operational